Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

368

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasm
Neoplasm Metastasis

Interventions

DRUG: Abemaciclib
DRUG: Fulvestrant
DRUG: Placebo

Sponsor

Eli Lilly and Company